Adra1B Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{-
| Attribute |
Value |
| Protein Name |
ADRA1B, Alpha-1B Adrenergic Receptor |
| Gene Symbol |
adra1b |
| UniProt ID |
P15888 |
| Molecular Weight |
~50-60 kDa |
| Subcellular Localization |
Cell membrane, caveolin-rich domains |
| Protein Family |
Class A GPCR, α1-adrenergic family |
| Ligand |
Norepinephrine, epinephrine |
| Signal Transduction |
Gq/11 protein, PLCβ, Ca²⁺ |
-}}
The Alpha-1B Adrenergic Receptor (ADRA1B) is a G protein-coupled receptor that mediates the effects of norepinephrine and epinephrine on target tissues. It belongs to the α1-adrenergic receptor subfamily (ADRA1A, ADRA1B, ADRA1D) and plays important roles in cardiovascular function, smooth muscle contraction, and neurotransmission. In the central nervous system, ADRA1B is involved in arousal, attention, and stress responses.
ADRA1B has the canonical seven-transmembrane domain structure:
¶ Transmembrane Domain
- Seven α-helices: Cross the lipid bilayer
- Conserved sequence motifs: For ligand binding and G protein coupling
- Orthosteric binding pocket: Binds catecholamines
¶ Extracellular Domain
- N-terminal tail: Short extracellular sequence
- Loop regions: Three extracellular loops (ECL1-3)
¶ Intracellular Domain
- C-terminal tail: Contains phosphorylation sites
- G protein coupling region: Activates Gq/11 proteins
ADRA1B activates the Gq/11 signaling pathway:
- Norepinephrine/epinephrine binding
- Conformational change and G protein activation
- Phospholipase Cβ (PLCβ) activation
- PIP₂ hydrolysis → IP₃ + DAG
- Intracellular calcium increase
- PKC activation and smooth muscle contraction
- Vascular tone: Vasoconstriction in peripheral vasculature
- Smooth muscle contraction: Bladder, gastrointestinal tract, uterus
- Pupillary dilation: Radial muscle contraction
- Cardiac function: Positive inotropic effects
- CNS function: Arousal, stress response, attention
ADRA1B is expressed in:
- Peripheral tissues: Liver, kidney, heart, vasculature
- CNS: Cerebral cortex, hippocampus, hypothalamus
- Smooth muscle: Vascular, bladder, gastrointestinal
- Vascular dysfunction: α1-adrenergic signaling in cerebral vasculature
- Blood-brain barrier: ADRA1B in BBB regulation
- Cognitive function: Norepinephrine modulation of cognition
- Therapeutic potential: α1 antagonists in clinical trials
- Orthostatic hypotension: α1-adrenergic dysregulation
- Cardiovascular dysfunction: Autonomic failure in PD
- Evidence: Altered ADRA1B in PD studies
¶ Stroke and Vascular Cognitive Impairment
- Cerebral autoregulation: α1-adrenergic in blood flow control
- Ischemic injury: Role in post-stroke recovery
- Therapeutic targeting: Modulating cerebral vasculature
- Norepinephrine neuroprotection: ADRA1B-mediated effects
- Glial function: Astrocyte and microglia modulation
- Neuroinflammation: α1-adrenergic in glial responses
| Drug Class |
Mechanism |
Example |
Clinical Use |
| Antagonists |
Block receptor |
Prazosin |
Hypertension, PTSD |
| Partial agonists |
Weak activation |
Midodrine |
Orthostatic hypotension |
| Selective antagonists |
α1B-selective |
Terazosin |
Benign prostatic hyperplasia |
- Hypertension: First-generation α1 blockers
- Benign prostatic hyperplasia: Terazosin, doxazosin
- Post-traumatic stress disorder: Prazosin for nightmares
- Orthostatic hypotension: Midodrine
- Cognitive enhancement: α1 modulation in AD
- Stroke recovery: Enhancing arousal and recovery
- Neuroprotection: α1 agonist potential
- Peripheral ADRA1B as sympathetic activity marker
- Genetic variants and drug response
- Viral vector delivery to CNS
- CRISPR approaches for ADRA1B modulation
- Cryo-EM of α1-adrenergic receptors
- Allosteric modulator binding sites
- ADRA1B knockout mice: Hypotension, smooth muscle defects
- Transgenic models: Overexpression studies
- Disease models: Hypertension, stroke models
The study of Adra1B Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.